Please note: this event has been postponed to 16-19 November 2021
Advancing Global Business Strategy for BioPharma is a customised program designed to support early-stage biopharma executives. Participants will gain valuable skills and methodologies to develop effective business and investment strategies, optimise investor interest and accelerate their path to market. Two Masterclasses will be delivered in September and November. To gain maximum value from the program, interested participants can register for the series at a discounted rate or register for one Masterclass of interest.
Masterclass 1: Creating a Value Story for Your Product
This Masterclass program has three components (delivered in-person):
- BioForum: 16 November | 4:00pm – 6:30pm | ACMI, Swinburne Studio, Federation Square, Melbourne
- Masterclass Workshop: 17 November | 8:30am – 5:00pm | Melbourne Convention and Exhibition Centre, Clarendon Room A, 1 Convention Centre Place, South Wharf
- 30-minute Advisory Session: Individual meetings held across 18 and 19 November (individual meeting times to be advised)
Registration for this Masterclass program includes:
- Three complimentary registrations for colleagues to attend the BioForum
- Attendance at the full-day Masterclass for one company representative
- One 30-minute advisory session with Biointelect (two company representatives from your organisation may attend)
About this Masterclass
- Take a deep dive into the fundamentals of value propositions and their critical impact on business and investment strategy development
- Understand how value propositions are viewed by commercial partners vs investors and why this is important
- Explore strategies and solution considerations for IP, Quality and Regulatory pathways
- Become familiar with key considerations for reimbursement and health technology assessments and their impact on securing investment
- Explore the nuances of business models and their impact on the product development story
- Understand the value of Target Product Profiles and their practical uses when developing a clinical trial program
- Gain valuable skills and tools to implement when engaging regulators and pitching to investors
- Develop effective methodologies for creating pitch decks and attracting investment
At the conclusion, participants will have a deepened understanding of the significance of an effective value proposition, and the practical skills and tools necessary to implement early in business development to maximise investor interest and accelerate the path to market.
Leading Industry Experts
Biointelect Pty Ltd is a strategic planning and commercialisation consultancy helping early-stage biotech companies to develop and drive strategy, identify and evaluate new business opportunities and find the right partners. They advise clients on the spectrum of therapeutic development from start up through to post launch, with an Australian and a Global perspective. Read presenter bios below.
Register for one Masterclass:
- Members: $595
- Non-members: $695 p/p/masterclass
Register for the Series (2 Masterclasses):
- Members: $1,000
- Non-members: $1,250 p/p/series
Unsure if your organisation is a member? Check our member directory
This is a high value Masterclass Series. Heavily subsidised rates are made possible with sponsorship from the State Government of Victoria. The estimated value p/p/masterclass is $3,500.
Places are strictly limited and subject to confirmation by BioMelbourne Network.
Cancellation policy: A full refund can be issued up to 14 days prior to the event only. No refunds can be issued within 14 days of the event. In the event of postponement due to Government restrictions, registrations will be carried forward to a new date. Should the program be cancelled, or you are unable to attend on the rescheduled date, a full refund will be made available.
The 2021 Masterclass Series is sponsored by the State Government of Victoria, Department of Jobs, Precincts and Regions.
Masterclass 1 speaker biographies:
Mark Glover, General Manager, Biointelect
Mark Glover has over 30 years of very diverse experience across multiple therapeutic areas and interventions (Biologic, Pharmaceutical, Medical Devices (capital and consumables), OTC and FMCG); and most recently healthcare software in Australia, New Zealand, the UK and Asia.
He completed a BSC in Biochemistry with Honours from the University of Cardiff. Subsequently a Certificate in Health Economics from Monash University and a Diploma in Marketing Management from Macquarie University.
Mark’s healthcare career commenced in the UK with Pharmacia before migrating to Australia where he continued to work at Pharmacia. He was then one of the founding members of AMGEN Australia. Followed various increasing roles of responsibility in Sales and Marketing for Schering-Plough before securing his first General Manager Oceania role at Serono, followed by ANZ Managing Director at Allergan and then iNova.
Most recently he has been the ANZ Country Manager for Medidata, one of the world leading providers of software solutions for clinical trial data capture, management, and insights.
He also has previous Consulting experience with Commercial Eyes.
Mark has experience in M&A initiatives, including leading the sale of iNova (the Valeant subsidiary) to Private Equity in 2017.
Mark has energetically contributed to the broader industry for well over 20 years involved in many related industry associations, Medicines Australia (including on the Board), MTAA, AusBiotech, ARCS and ASMI. As well as active stakeholder engagement in the broader healthcare environment including Pharmacy Guild, PSA, PDL, GMBA, Federal and State bureaucrats and policy makers, and consumer groups.
Guillaume Herry, Director, Commercialisation, Biointelect
Guillaume Herry developed a versatile profile combining international hands-on operational biopharma and medical device industry experience across various roles of increased responsibility (incl. CEO position), with successful strategic consulting experience advising the industry both locally and internationally.
With experience working in the US, Europe and Australia, Guillaume has developed expertise and a strong track record in formulation and implementation of growth strategies, strategic market access & policy, driving innovation in healthcare across new product & service development, commercialisation, corporate and business development, financial modelling, operational and general management (including sales & marketing, full company P&L ownership).
Guillaume is genuinely interested and enthusiastic about furthering innovation in healthcare and contributing to timely patient access to innovative medicines. Guillaume is an active member of the Policy Scanning Working Group at Medicines Australia and is also the inventor of several granted patents currently used in various commercial ventures.
Guillaume holds an MBA from the Australian Graduate School of Management at University of New South Wales Business School, a Master’s Degree in Engineering for Health and Drugs (Biotechnology, Health and Management) from the University Joseph Fourier in Grenoble (France) and a Master’s Degree in Entrepreneurship in Life Sciences & Technologies from the University Paris-Sud X (France).
Dr Patricia Vietheer, Director, R&D Strategy & Planning, Biointelect
Patricia Vietheer has over 18 years of scientific experience in the Life Sciences industry. She holds a Bachelor of Science degree with First Class Honours from University of Queensland and a PhD in Microbiology at Monash University. She also holds an MBA majoring in Strategy & Planning at Deakin University. In 2015, Patricia completed the Molecules to Medicine Internship on Commercialization.
A specialist in infectious diseases, molecular biology and viral immunology, Patricia’s career began in the research laboratory working on the preclinical evaluation of a versatile vaccine platform collaborating with industry. She has since held a range of roles in research; business development, project management and program development where she has helped translate scientific ideas into public health solutions. Patricia’s deep experience in early-stage preclinical R&D especially in vaccine development, technology transfer and in vivo animal studies, has been instrumental in project planning and execution often working in cross-discipline, multi-country projects driving projects towards successful outcomes.
Patricia has been a recipient of multiple awards including the NHMRC Dora Lush BioMedical Award, Australian Defence Force Prince of Wales Award and the Australian Centre for HIV & Hepatitis Virology Young Investigator’s Award. She has made substantial contribution to numerous granted patents, co-authored multiple scientific publications in peer-reviewed journals and has presented at numerous national and international conferences.
Fiona Seddon, Senior Regulatory Affairs Manager, Biointelect
Fiona Seddon has over 25 years of regulatory affairs experience in Australia, New Zealand the USA and Europe. Her experience includes a broad spectrum from emerging and new product development through to clinical trials and registration as well as regulatory strategy and compliance. She holds a Bachelor of Science degree with a double major in biochemistry and microbiology and a Masters of Clinical Chemistry.
Fiona started her career in the laboratory developing methods for analysis, purification, and formulation across academic, clinical and industry projects. She then moved to Regulatory Affairs, applying Regulatory Science to development of pharmaceutical and biotechnology products. She specializes in guiding pharmaceutical product development for regulatory compliance. The results from this strategy support high quality due diligence packages for commercialization. Examples include development and implementation of product specification, characterization, technical transfer and comparability strategies, leading multi-national cross-discipline teams towards successful project outcomes.
Fiona has worked in Regulatory Affairs with CSL/Seqirus and as a regulatory consultant for 7 years and has a diverse skillset in medical and scientific writing, regulatory and quality. Fiona has guided projects for small molecule, bacterial, biotechnology, and diagnostics product development and prepared the clinical trial and marketing applications for local and international submissions.
Dr Camille Shanahan, Consultant, Biointelect
Camille Shanahan has over 15 years of clinical, scientific and commercialisation experience in the biopharma sector. She holds a PhD from the University of Melbourne, a Masters Degree from York University (Canada) and a Bachelor of Prosthetics and Orthotics with Honours from La Trobe University. She has postdoctoral and graduate research experience in Biomechanics, Neuroscience and Ergonomics as well as Prosthetics and Orthotics clinical experience in public and private healthcare settings. Camille is a participant in the MTP Connect/UQ 2020 Bridge Program which aims to boost the commercial outputs of Australian pharmaceutical research.
Camille has extensive project management experience from her roles in Major Projects and Stem Cells Australia at the University of Melbourne. Camille previously project managed major infrastructure projects in Science, Technology, Engineering, Maths and Medicine at the University of Melbourne. Major Projects are significant initiatives with strategic impact and partnership capacity that carry the potential for substantial opportunity and risk. Typically, these are large scale infrastructure projects with an investment value greater than $50 million. These projects involved working closely with stakeholders, consultants and external organisations to develop ideas into projects, including concept planning, options development, feasibility and risk assessment, business case development and project implementation.
At Stem Cells Australia Camille developed translational opportunities from teams of stem cell researchers across Australia. Camille project managed teams developing cell and gene therapies for kidney disease, blindness, epilepsy and heart disease. The role included reviewing the of scope and capacity of stem cell research and the assembly of stem cell teams towards specific disease areas, clinical translation programs and commercialisation opportunities. Camille developed and implemented training and capacity building in commercialisation and business development for teams developing stem cell and gene therapy products. Camille worked closely with the teams on business plans and strategic planning for their products. Camille facilitated key connections between researchers, clinicians and industry to assist in project success of the projects.
Camille is committed to contributing to the translation of medical research into clinical application.
Nathan Fox, Consultant, Biointelect
Nathan Fox is a health economist with more than six years’ experience across the Australian and New Zealand pharmaceutical, medical services and devices markets.
Nathan has worked predominantly in health technology assessment and has a practical understanding of reimbursement systems and processes. Nathan has experience developing submissions for global pharmaceutical companies to the Pharmaceutical Benefits Advisory Committee (PBAC) for reimbursement and listing on the Pharmaceutical Benefits Schedule (PBS), and to New Zealand’s Pharmaceutical Management Agency (PHARMAC). This role has seen Nathan develop considerable experience in the costing, economic evaluation and financial implications analysis, submission preparation and commentary.
Nathan’s work for the New Zealand Government’s PHARMAC saw him responsible for considering the therapeutic positioning, health economic and financial implications of potential funding options for medicines, vaccines and rare diseases. Here Nathan worked with key opinion leaders (KOLs) to understand the New Zealand treatment landscape, define treatment positioning and identify value propositions for funding of specific patient markets. He also contributed to the PHARMAC prioritisation process used to compare and rank potential funding options, leading to successful funding decisions across numerous therapeutic areas including dermatology, rheumatology, gastrointestinal, oncology, rare disorders and infectious diseases.
Recently, Nathan worked as part of a contract team at the University of Sydney, critiquing and developing assessments of medical services, devices, and diagnostics for the Australian Department of Health’s Medical Services Advisory Committee (MSAC). In this role Nathan was responsible for project management of departmental engagements. Nathan examined the clinical positioning, economic and financial impacts of potential funding options, engaging with clinical KOLs and departmental policy makers to understand newly emerging technologies and market segments.
Nathan Fox joined Biointelect in early 2021. He holds a Master’s degree in economics from Erasmus University Rotterdam, with a specialisation in health economics and is currently completing a Master’s in Public Health at the University of Sydney.